EUVIMEDEUVIMED entdecken
Open Access

Modular Platform for Therapeutic Drug Delivery Using Trifunctional Bio-Orthogonal Macromolecular Conjugates

Danmeng Luo, Ning Wang iD, Hannah Major-Monfried, John Ralls, Sophia Rha, Stacy A Maitland, Karthikeyan Ponnienselvan, Makiko Yamada, Daniel E Bauer, Scot A Wolfe, Alex Kentsis iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Danmeng Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Drug Delivery Systems, Macromolecular Substances. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted delivery of macromolecular therapeutics holds great promise for overcoming the limitations of conventional small molecules, enabling the modulation of protein-protein interactions and precise genome editing. However, efficient, safe, and cell type-specific delivery remains a major challenge. To address this, we developed a modular platform for synthesizing heterotrifunctional bio-orthogonal macromolecular conjugates (BMCs) by engineering diverse combinations of targeting ligands, cell-penetrating peptides (CPPs), and bioactive cargos. We optimized facile bioconjugation chemistries to generate BMCs with improved yields, structural integrity, and activity. Modular BMCs accommodate diverse components, including antibodies and receptor ligands for targeting, CPPs for intracellular trafficking, and optical probes, therapeutic peptidomimetics, and CRISPR-Cas9 nuclease as cargo to confer specific biological activities. We assayed their utility across multiple applications: BMCs with fluorescently labeled cargo revealed endosomal escape and intracellular accumulation; peptidomimetic MYB transcription factor inhibitor BMCs exhibited potent antileukemic activity against acute myeloid leukemia cells; and Cas9 BMCs achieved rapid delivery and cell type-specific gene editing in human cells. The BMC approach enables the customizable delivery of functional macromolecules, nominating BMCs as a broadly applicable platform for biomedical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Penetrating PeptidesDrug Delivery SystemsMacromolecular SubstancesHumansGene EditingCell Line, TumorPeptidomimeticsLigandsCRISPR-Cas Systems

Substanzen

Cell-Penetrating PeptidesMacromolecular SubstancesPeptidomimeticsLigands

Autor:innen und Institutionen

  • Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.
  • Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, United States.
  • Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts 01605, United States.
  • Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Harvard Medical School, Boston, Massachusetts 02115, United States.
  • Departments of Pediatrics, Pharmacology, and Physiology & Biophysics, Weill Cornell Medical College, Cornell University, New York, New York 10021, United States.

ORCID-Profile: Ning Wang, Alex Kentsis

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Cancer Institute
  • Doris Duke Charitable Foundation
  • Commonwealth Foundation for Cancer Research Foundation
  • Cancer Research and the Center for Experimental Therapeutics, Memorial Sloan-Kettering Cancer Center

Zitieren

APA

Luo, D., Wang, N., Major-Monfried, H., Ralls, J., Rha, S., Maitland, S. A., Ponnienselvan, K., Yamada, M., Bauer, D. E., Wolfe, S. A., & Kentsis, A. (2025). Modular Platform for Therapeutic Drug Delivery Using Trifunctional Bio-Orthogonal Macromolecular Conjugates. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00440

Vancouver

Luo D, Wang N, Major-Monfried H, Ralls J, Rha S, Maitland SA, et al. Modular Platform for Therapeutic Drug Delivery Using Trifunctional Bio-Orthogonal Macromolecular Conjugates. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00440

BibTeX
@article{Luo2025,
  author = {Luo, Danmeng and Wang, Ning and Major-Monfried, Hannah and Ralls, John and Rha, Sophia and Maitland, Stacy A and Ponnienselvan, Karthikeyan and Yamada, Makiko and Bauer, Daniel E and Wolfe, Scot A and Kentsis, Alex},
  title = {Modular Platform for Therapeutic Drug Delivery Using Trifunctional Bio-Orthogonal Macromolecular Conjugates},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00440}
}
Kostenlos starten →